Overview

Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

Status:
Completed

Trial end date:
2019-08-28

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and safety of actovegin in participants with peripheral arterial disease (PAD) Fontaine Stage IIB.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Actovegin